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Abstract
BACKGROUND: Published case series have suggested a potential association between human 
papillomavirus (HPV) vaccination and primary ovarian insufficiency (POI). We describe POI 
incidence and estimate POI risk after HPV; tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis, adsorbed (Tdap); inactivated influenza (II); and meningococcal conjugate (MenACWY) 
vaccination.
METHODS: We searched Kaiser Permanente Northwest electronic health records for outpatient 
diagnoses suggestive of POI in female patients aged 11 to 34 years between 2006 and 2014. We 
reviewed and adjudicated the medical record to confirm diagnoses and estimate symptom onset 
dates. We excluded cases with known causes and calculated the incidence of idiopathic POI. We 
estimated risk by calculating hazard ratios and 95% confidence intervals (CIs).
RESULTS: From a cohort of 199 078 female patients, we identified 120 with diagnoses 
suggestive of POI. After adjudication and exclusion of 26 POI cases with known causes, we 
confirmed 46 idiopathic POI cases. POI incidence was low in 11- to 14-year-olds (0.87 per 1 000 
000 person-months) and increased with age. One confirmed case patient received the HPV vaccine 
23 months before the first clinical evaluation for delayed menarche. The adjusted hazard ratio was 
0.30 (95% CI: 0.07–1.36) after HPV, 0.88 (95% CI: 0.37–2.10) after Tdap, 1.42 (95% CI: 0.59–
3.41) after II, and 0.94 (95% CI: 0.27–3.23) after MenACWY vaccination.
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CONCLUSIONS: We did not find a statistically significant elevated risk of POI after HPV, Tdap, 
II, or MenACWY vaccination in this population-based retrospective cohort study. These findings 
should lessen concern about POI risk after adolescent vaccination.
Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
United States1 and is associated with several cancers as well as anogenital warts. Since 
2006, HPV vaccines have been licensed and recommended for use in adolescent girls by the 
Advisory Committee on Immunization Practices.2 Rates of HPV vaccination have lagged 
behind coverage rates for other recommended adolescent vaccinations, such as tetanus 
toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap) and 
meningococcal conjugate (MenACWY). On the basis of national coverage estimates from 
2016, 65% of 13- to 17-year old girls received at least 1 HPV vaccination and only 49.5% 
were up to date with the series, compared with ~88% of adolescents who had received the 
Tdap vaccine.3 Although authors of large population-based studies have demonstrated the 
safety of HPV vaccination, parental safety concerns, including potential impacts on future 
fertility, are often cited as 1 reason for lower HPV coverage.4–8
Concern about infertility after HPV vaccination developed after case series were published 
describing the onset of primary ovarian insufficiency (POI), also known as premature 
ovarian failure or premature menopause, within 12 months after vaccination in 6 young 
women from 13 to 21 years of age.9,10 POI is characterized by either the dysfunction or 
depletion of ovarian follicles, menopausal symptoms (eg, amenorrhea or hot flashes), or 
reduced fertility. In girls <20 years of age, POI is uncommon with an estimated prevalence 
of 1 case per 10 000.11 Chromosomal abnormalities, including Turner syndrome and Fragile 
X syndrome, as well as the gonadotoxic treatment of cancer (chemotherapy or radiation) are 
known etiologies for POI; however, most POI is idiopathic but may be associated with 
underlying autoimmune (eg, rheumatoid arthritis or systemic lupus erythematosus), 
metabolic (eg, galactosemia), or infectious disease (eg, mumps).11
Reports of POI after HPV vaccination have garnered national media attention and have 
circulated widely on social media and other Internet sites,12–15 but to our knowledge, no 
population-based studies of POI after HPV vaccination have been conducted to date. The 
published case series must be interpreted with caution because the authors of the series 
included small samples of young women presenting for care at selected clinical sites, relied 
on self-reported vaccine exposures, and lacked controls. We conducted a retrospective cohort 
study to (1) identify and describe characteristics of idiopathic POI diagnosed in female 
patients 11 to 34 years of age, (2) describe the prevalence and age-specific incidence of POI, 
and (3) estimate the risk of idiopathic POI in female patients after HPV vaccination or other 
recommended adolescent vaccinations (Tdap, MenACWY, and inactivated influenza [II]).
METHODS
The Vaccine Safety Datalink (VSD) is a collaborative project involving 8 integrated health 
care delivery systems and the Centers for Disease Control and Prevention. The current VSD 
study was conducted at a single site, Kaiser Permanente Northwest (KPNW), serving a 
population of ~570 000 members in Oregon and Washington. The study protocol, data 
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collection tools, and study procedures were approved by the KPNW Institutional Review 
Board.
Study Period and Population
We identified all female patients 11 to 34 years of age with at least 30 days of health plan 
enrollment at KPNW from August 1, 2006, to December 31, 2014. This study period was 
selected to maximize the potential number of POI cases in the period after HPV vaccine 
licensure and recommendation. We also wanted to focus on female patients who were age-
eligible for HPV vaccination and to allow for the follow-up of women who were vaccinated 
at 26 years of age. Cohort participants were managed until health plan disenrollment, the 
participant’s 35th birthday, or the end of the study period, whichever occurred first.
Case Ascertainment
We identified presumptive cases of POI among young women in the cohort by searching 
electronic health record (EHR) databases for outpatient encounters coded with International 
Classification of Diseases, Ninth Revision (ICD-9) codes for premature menopause 
(256.31), other ovarian failure (256.39), other ovarian dysfunction (256.8), and unspecified 
ovarian dysfunction (256.9). We then manually reviewed the medical record of the 
presumptive cases to collect data on diagnostic and other laboratory testing, symptom onset, 
and other POI risk factors. The study abstraction form was developed in partnership with 
subject matter experts from the Centers for Disease Control and Prevention and 2 KPNW 
obstetrics and gynecology providers.
Each presumptive case was abstracted by at least 1 study investigator (MLH, SAI, and 
ALN). Presumptive cases that were clearly miscoded or ruled out diagnoses, or cases for 
whom adequate medical records were not available, were excluded from additional review. 
Remaining presumptive cases were then abstracted again independently by a second 
investigator. Any discrepant information obtained by the 2 independent abstractions was 
discussed and resolved by the investigator team. As part of the medical record review, we 
either recorded the date of POI symptom onset when noted or estimated the onset date on 
the basis of other information documented in the record (eg, age at onset or date of last 
menses) or the earliest encounter for delayed menarche, amenorrhea, oligomenorrhea, or 
infertility evaluation.
After medical record review, we excluded cases of POI with a known cause, including those 
with surgical menopause (ie, removal of the ovaries), those with a genetic condition, such as 
Fragile X Syndrome, Turner syndrome, or another X-linked chromosomal disorder, and 
those who had received either chemotherapy or radiotherapy for cancer. The remaining 
idiopathic presumptive POI cases were reviewed and adjudicated by an obstetrics and 
gynecology nurse practitioner to confirm case status.
The American College of Obstetricians and Gynecologists (ACOG) guidelines for the 
diagnosis of POI16 include the presence of menstrual irregularity for at least 3 months and 
elevated follicle-stimulating hormone (FSH) in the postmenopausal range and low estradiol 
levels on 2 separate occasions. Other clinical tests used to establish or refine the diagnosis 
include karyotyping, adrenal antibody titers, pelvic ultrasonography, and antimullerian 
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hormone levels. Many presumptive cases could not be classified with the ACOG definition 
because the diagnostic tests were not consistently ordered by the treating providers. The 
clinical adjudicator was instructed to classify presumptive cases as probable POI if there was 
strong evidence to support a diagnosis of POI and/or most or all of the ACOG definition was 
met; possible POI was classified if there was some evidence to support a diagnosis of POI, 
but the ACOG definition was not met; and not POI was classified if the case clearly did not 
meet the ACOG definition.
Descriptive Analysis
We calculated the proportion of the presumptive cases identified by each ICD-9 code that 
met the case definitions of probable and possible POI as defined above after medical record 
review and adjudication. We also described demographic characteristics, diagnostic testing 
patterns and results, symptom onset, and time to diagnosis among confirmed (probable and 
possible) idiopathic cases.
POI Incidence
We calculated the prevalence of idiopathic diagnosed POI by dividing the number of 
confirmed (probable and possible) cases identified during the study period by the number of 
eligible cohort members; POI incidence was calculated by using eligible person-months as 
the denominator. Person-months were calculated based on the beginning and end of the 
study period and each individual’s health plan enrollment dates as described above. We 
calculated age-stratified (11–14, 15–18, 19–22, 23–26, 27–30, and 31–34 years) rates on the 
basis of the date of POI diagnosis and calculated 95% confidence intervals (CIs) for these 
rates on the basis of the Poisson distribution.
Risk Estimation
We used time-dependent Cox proportional hazards modeling to estimate the hazard ratios 
(HRs) and 95% CIs associated with HPV, Tdap, MenACWY, or II exposures independently. 
Because we observed long intervals between symptom onset and POI diagnosis, we limited 
the cases included in the models to those with symptom onset after August 1, 2006 (ie, the 
date of HPV vaccine availability at KPNW). To capture data on additional adolescent 
vaccines that were licensed before HPV, we identified all vaccine exposures in the cohort 
occurring 1 year before (August 1, 2005) and during the study period. Vaccinations were 
identified by using both the KPNW EHR databases and the Oregon and Washington state 
immunization information systems to increase the capture of vaccinations received outside 
of the KPNW delivery system.
To calculate person-time in the Cox models, we managed subjects until the symptom onset 
dates for cases, and the end of the study period, the 35th birthday, or last health plan 
disenrollment during the study period for noncases. We defined vaccine exposure as the first 
dose received of a specific vaccine from 1 year before the start of the observation period 
through the end of follow-up. In the absence of any data to suggest a biologically plausible 
exposure window, we considered any person-time after a specific vaccine exposure to be 
exposed person-time. We therefore did not specifically model multiple doses of a vaccine or 
a combination of multiple vaccines. We estimated both crude and age-adjusted HRs for each 
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vaccine and described the timing of vaccine exposures related to POI symptom onset. On the 
basis of post hoc power calculations, we estimated the smallest significant HRs we could 
detect with 80% power, and α = .05 were 3.23 for HPV, 2.94 for Tdap, 2.94 for II, and 3.45 
for MenACWY exposures.
RESULTS
During the study period (August 1, 2006, to December 31, 2014), 199 078 female patients 
11 to 34 years of age had at least 30 days of health plan enrollment in KPNW; 119 078 
received Tdap, 84 783 received II, 58 871 received HPV, and 46 231 received MenACWY 
vaccination. From this cohort, we identified 120 patients with an outpatient diagnosis of 
premature menopause, ovarian failure, or ovarian dysfunction (Fig 1). We excluded 41 
presumptive cases after the initial chart review; 35 patients had a specific diagnosis other 
than POI (miscoded POI diagnoses), 4 patients were ruled out POI diagnoses, and 2 patients 
had inadequate medical records available for review. After the second round of chart review, 
we excluded 26 POI cases with a known cause, including the following: 6 patients with 
surgical menopause, 12 patients with a genetic disorder, and 14 patients treated for cancer 
(note categories are not mutually exclusive). The clinical adjudicator classified 7 
presumptive cases as not POI, leaving 46 confirmed, idiopathic POI cases (33 probable and 
13 possible).
Two ICD-9 codes, 256.8 (other ovarian dysfunction) and 256.9 (unspecified ovarian 
dysfunction), yielded no medical record–confirmed POI cases. Of the 28 presumptive cases 
diagnosed with ICD-9 code 256.31 (premature menopause), 50% were classified as possible 
or probable idiopathic POI after full review and adjudication. Similarly, we classified 43% 
of the 76 presumptive cases diagnosed with ICD-9 256.39 (other ovarian failure) as possible 
or probable idiopathic POI.
More than one-half of the confirmed POI cases were patients who were diagnosed at ≥27 
years of age, and only 1 patient was diagnosed at <15 years of age (Table 1). Most patients 
were white (61%) and non-Hispanic (67%) individuals. Six patients (13%) presented with 
primary amenorrhea, and 8 patients (17%) had a comorbid autoimmune disease diagnosis. 
Symptom onset could not always be estimated if there was insufficient documentation in the 
medical record or if the patient presented with primary amenorrhea. Excluding these cases, 
the median time from symptom onset to diagnosis was ~3 years (range: 75 days–16 years, 
data not shown).
Most patients had at least 1 FSH (94%) or estradiol (78%) test in their medical record, but 
multiple tests were less common, especially for estradiol (Table 2). Only 9 (20%) confirmed 
cases met the strict ACOG diagnostic criteria for POI. Testing for antiadrenal and 
thyroperoxidase antibodies was uncommon, as were abnormal antimullerian hormone levels.
The prevalence of idiopathic POI in the study period was 2.31 per 10 000 female patients. 
The incidence of diagnosed POI increased with age, from a low of 0.87 per 1 000 000 
person-months in 11- to 14-year-olds to a peak of 12.85 per 1 000 000 person-months in 30- 
to 34-year-olds (Table 3).
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Of the confirmed cases, 18 (39%) had symptom onset before August 1, 2006, and were 
excluded from Cox models. Of the remaining 28 cases, only 1 was vaccinated against HPV 
before symptom onset; this 16-year-old girl received her third dose of HPV vaccine ~23 
months before the estimated symptom onset. This patient presented with primary 
amenorrhea, so the symptom onset date was estimated as the earliest documented encounter 
for clinical evaluation of delayed menarche; POI onset likely occurred before this estimated 
date. The age-adjusted HR of POI after HPV vaccination was 0.30 (95% CI: 0.07–1.36) 
(Table 4).
Six confirmed patients with POI were vaccinated with Tdap (5–40 months before symptom 
onset), 11 patients were vaccinated with II (2–91 months before symptom onset), and 3 
patients were vaccinated with MenACWY (2–27 months before symptom onset). The age-
adjusted HR of POI was 0.88 (95% CI: 0.37–2.10) with Tdap, 1.42 (95% CI: 0.59–3.41) 
with II, and 0.94 (95% CI: 0.27–3.23) with MenACWY vaccination (Table 4).
DISCUSSION
To our knowledge, this is the first population-based study in which POI is evaluated as a 
possible vaccine adverse event. We did not find an elevated risk of POI after HPV 
vaccination, nor did we find any elevated risk after Tdap, II, or MenACWY vaccination. We 
observed only 1 patient with POI who possibly had symptom onset after HPV vaccination 
from a population of 58 871 young women who received the HPV vaccine during the study 
period. If POI is triggered by HPV or other adolescent vaccine exposure, we would have 
expected to see elevated incidence in the younger women who were most likely to be 
vaccinated, but instead we observed higher incidence in older women (>26 years of age), 
which is consistent with 1 other population-based study of POI prevalence.11 With our study, 
we overcame some of the limitations of the previously published case reports describing POI 
after HPV vaccination, including small sample sizes and lack of population-based controls, 
and this should provide additional reassurance about the safety of HPV vaccination with 
respect to POI risk. However, it should be noted that this study was underpowered to detect 
small increases in POI risk associated with vaccination.
Studying POI as a vaccine adverse event is challenging for many reasons. First, the time 
from symptom onset to diagnosis with POI may be variable or long.17 We observed that the 
median time from symptom onset to POI diagnosis was 3 years in this cohort, and the 
authors of another study reported that 25% of patients required >5 years from onset to 
diagnosis.17 We were able to capture cases that were diagnosed in our health plan, but we 
may have misclassified some true cases of POI who were symptomatic but did not have a 
long enough follow-up time to reach a diagnosis. However, because 81% of our cohort was 
managed for >24 months (mean follow-up time = 5.14 years), we consider that this potential 
for misclassification was minimal.
Secondly, diagnoses of POI are difficult to accurately identify. We found that using the 
ACOG diagnostic definition was difficult to implement in observational studies derived from 
EHR data because patients often did not undergo all of the diagnostic testing required to 
meet the definition.16 In our health care system, we observed that patients were likely to 
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receive 1 FSH and 1 estradiol test but not the multiple tests required for positive diagnosis 
based on the ACOG definition; review and adjudication by a women’s health clinician was 
therefore needed to establish case status. Additionally, we excluded some POI cases with a 
known cause, such as certain genetic disorders like Turner syndrome, and focused on 
idiopathic POI that might be triggered by vaccination. Other case definitions for 
epidemiological studies have varied, and many researchers did not exclude POI with a 
known cause, making comparison of rates and estimation of risk difficult across studies.
18–20
Another challenge of this study, and all observational studies of POI, is adequately capturing 
hormonal contraceptive use, which may mask the symptoms and onset of POI and can result 
in misclassification.21, 22 Many of the patients we observed in this cohort were women in 
their late 20s who stopped using contraceptives because they were attempting to conceive, 
and subsequently presented for diagnostic evaluation of amenorrhea and infertility. We were 
not able to adjust for contraceptive use because these data are not routinely included in the 
VSD data files. Additionally, the capture of contraceptives for young women may not be 
complete in health plan databases if young women are receiving and filling prescriptions at 
outside pharmacies and clinics. We believe that the potential misclassification of case status 
in women using hormonal contraceptives would be nondifferential because authors of 
previous studies have not found that hormonal conceptive use is more prevalent among 
vaccinated young women compared with unvaccinated women.23,24
If vaccination is associated with POI onset, the exposure would most likely induce POI 
through an autoimmune pathway.25,26 There are no mechanistic studies available to suggest 
what a biologically plausible exposure window might be, and so we examined any exposure 
before symptom onset. Using this long exposure window has the potential to mask a true 
acute risk of POI after vaccination, but limiting our study to shorter windows might miss an 
association that requires a longer latent period.
All vaccinated patients were exposed at least 2 months before symptom onset, and many 
were vaccinated years before onset. The 1 patient exposed to HPV who was observed was 
vaccinated nearly 2 years before the estimated symptom onset date, which is not consistent 
with the authors of case reports who observed onset within 12 months of vaccination.9,10 
Although we did not formally test, we did not observe any temporal clustering of vaccine 
exposures among patients.
CONCLUSIONS
Concern about a potential association between HPV vaccination and POI generated by 
earlier published case series and media attention may negatively impact decision-making 
about HPV vaccine acceptance. We found no evidence of increased risk of POI after HPV 
vaccination, or other routine adolescent vaccination exposures, in this population-based 
retrospective cohort study with nearly 200 000 young women. Despite the challenges and 
limitations discussed above, we believe this study should lessen concern surrounding 
potential impact on fertility from HPV or other adolescent vaccination.
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ABBREVIATIONS
ACOG American College of Obstetricians and Gynecologists
CI confidence interval
EHR electronic health record
FSH follicle-stimulating hormone
HPV human papillomavirus
HR hazard ratio
ICD-9 International Classification of Diseases, Ninth Revision
II inactivated influenza
KPNW Kaiser Permanente Northwest
MenACWY meningococcal conjugate
POI primary ovarian insufficiency
Tdap tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, 
adsorbed
VSD Vaccine Safety Datalink
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WHAT’S KNOWN ON THIS SUBJECT:
Authors of published case series have suggested an association between human 
papillomavirus vaccination and primary ovarian insufficiency, but no population-based 
epidemiological studies have been reported.
WHAT THIS STUDY ADDS:
No significant elevated risk of primary ovarian insufficiency after adolescent vaccination 
was observed in this population-based retrospective cohort study of nearly 200 000 young 
women. These findings should lessen concern about potential impact on fertility from 
adolescent vaccination.
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FIGURE 1. 
Ascertainment and adjudication of POI cases, KPNW, August 2006 to December 2014.
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TABLE 1
Characteristics of Confirmed Idiopathic POI Cases, KPNW, August 2006 to December 2014
Characteristic N (%)
Age at diagnosis, y
 11–14 1 (2)
 15–18 5 (11)
 19–22 4 (9)
 23–26 7 (15)
 27–30 13 (28)
 31–34 16 (35)
Age at estimated symptom onset, y
 11–14 6 (13)
 15–18 9 (20)
 19–22 5 (11)
 23–26 11 (24)
 27–30 10 (28)
 31–34 5 (11)
Race
 White 28 (61)
 Multiracial or people of color 5 (11)
 Unknown 13 (28)
Ethnicity
 Latina and/or Hispanic 7 (15)
 Non-Latina or non-Hispanic 31 (67)
 Unknown 8 (17)
Autoimmune comorbid diagnosis 8 (17)
Primary amenorrhea 6 (13)
Family history of POI 4 (9)
Family history of infertility 4 (9)
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TABLE 2
Diagnostic Testing for POI, KPNW, August 2006 to December 2014
Test N (%)
ACOG tests
 FSH tested 43 (94)
 FSH tested on at least 2 separate occasions 33 (72)
 FSH was abnormala on at least 2 separate occasions 33 (72)
 Estradiol tested 36 (78)
 Estradiol tested on at least 2 separate occasions 16 (35)
 Estradiol was abnormala on at least 2 separate occasions 9 (20)
 Met ACOG POI case definitionb 9 (20)
Other diagnostic tests
 Abnormal antimullerian hormone 4 (9)
 Antiadrenal antibodies 0 (0)
 Thyroperoxidase antibodies 4 (9)
aAbnormal is defined as being in the postmenopausal range by using reference values documented in the medical record. Reference values varied 
by patient age, reference laboratory, and the timing of collection relative to menstrual cycle and hormonal therapy use.
bACOG POI case definition requires the presence of menstrual irregularity for at least 3 mo, elevated FSH in the postmenopausal range, and low 
estradiol levels on 2 separate occasions.
Pediatrics. Author manuscript; available in PMC 2019 September 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Naleway et al. Page 15
TABLE 3
Age-Specific Incidence of Diagnosed POI, KPNW, August 2006 to December 2014
Age at Initial Diagnosis, y Cases Person-Mo Incidence per 1 000 000 Person-Mo (95% CI)
11–14 1 1 151 805 0.87 (0.12–6.16)
15–18 5 1 226 602 4.08 (1.70–9.79)
19–22 4 1 109 535 3.61 (1.35–9.61)
23–26 7 1 059 109 6.61 (3.15–13.86)
27–30 13 1 151 201 11.29 (6.56–19.45)
31–34 16 1 245 185 12.85 (7.87–20.97)
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TABLE 4
POI Incidence in Vaccinated and Unvaccinated Young Women and Associated HRs With 95% CIs
Cases Vaccinated Before Symptom 
Onset Unexposed Cases Unadjusted HR (95% CI) Age-Adjusted HR (95% CI)
HPV 1 27 0.27 (0.06–1.16) 0.30 (0.07–1.36)
Tdap 6 22 0.78 (0.34–1.84) 0.88 (0.37–2.10)
MenACWY 3 25 0.70 (0.24–2.03) 0.94 (0.27–3.23)
II 11 17 1.35 (0.57–3.22) 1.42 (0.59–3.41)
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